Drug Profile

Research programme: AMP activated protein kinase therapeutics - Poxel

Alternative Names: AMPK activators - Poxel

Latest Information Update: 28 Nov 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

28 Nov 2024 No recent reports of development identified for research development in Adrenoleucodystrophy in France
09 Jul 2021 Early research in Adrenomyeloneuropathy in France (unspecified route) before July 2021 (Poxel Pharma pipeline, July 2021)
22 Oct 2020 AMP-activated protein kinase therapeutics - Poxel is available for licensing as of 22 Oct 2020. https://www.poxelpharma.com/en_us/about (Poxel website, October 2020)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com